Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?

Öztürk Selçuk, Elçin Ayşe Eser, Elçin Yaşar Murat

Table 1 Clinical trials recorded in www.clinicaltrials.gov database about stem cells and COVID-19 infection by 27th of March 2020.

Identifier Phase Status Location Cell type Estimated enrollment Primary outcome measure NCT04252118 1 Recruiting China MSC 20 - Size of lesion area by chest radiograph or CT - Side effects in MSC treatment group NCT04276987 1 Not yet recruiting China MSC-derived exosomes 30 - Adverse and severe adverse reaction - Time to clinical improvement NCT04299152 2 Not yet recruiting N/A SCE-treated MNC 20 - Number of patients unable to complete SCE therapy NCT04273646 N/A Not yet recruiting China UC-MSC 48 - Pneumonia severity index - Oxygenation index NCT04288102 1-2 Recruiting China MSC 90 - Size of lesion area and severity of pulmonary fibrosis by CT NCT04302519 1 Not yet recruiting N/A Dental pulp MSC 24 - Disappear time of ground-glass shadow in the lungs NCT04313322 1 Recruiting Jordan WJ-MSC 5 - Clinical outcome - CT scan - RT-PCR results NCT04293692 N/A Withdrawn China UC-MSC N/A - Size of lesion area by chest imaging - Blood oxygen saturation NCT04269525 2 Recruiting China UC-MSC 10 - Oxygenation index